SION Company Profile and Key Details

Sionna Therapeutics, Inc. (NASDAQ:SION) closed at $41.14 USD, losing -$0.25 (-0.60%) from the previous close of $41.39. The stock is currently mid-range between its 52-week high and low $7.25 and $45.00. With a market capitalization of about $1.84 billion, Sionna Therapeutics, Inc. is classified as a small-cap and shows higher-than-market volatility (beta ~3.46). Key stats such as the average daily volume over the past year has been around 306.55 thousand shares, in line with its 52-week average. Headquartered in Waltham, MA, Sionna Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael Cloonan, the company employs approximately 41 people and listed since February 07, 2025. Sionna Therapeutics, Inc. is a biopharmaceutical company.

Sionna Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.64. This means the shares are trading above this model’s fair value.

Wall Street analysts project EPS growth of 45.26% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 2 Strong Buy ratings, 4 Buy ratings, 1 Hold ratings, 0 Sell rating and 1 Strong Sell ratings. Price targets range from $60.00 to $22.00. The high target offers 45.84% upside. The low target suggests -46.52% downside. The mean target is $39.62. This offers -3.69% upside. Sionna Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended November 05, 2025, missed forecasts by -11.54%. The prior quarter beat by -39.71%. Over the last six quarters, Apple has recorded several small beats. These include 492.98% in March 20, 2025.

Sionna Therapeutics, Inc. has 44.14 million shares outstanding. The public float is 11.04 million shares, elevated short interest at 13.71% of float. This equals 3.60 million shares. The short ratio is 22.4 days. Institutional investors hold 105.32% of the float. Insiders own 7.01%. TPG GP A, LLC holds 6.74 million shares, ORBIMED ADVISORS LLC has 3.56 million shares and Thompson Peter A. has 3.56 million shares. Over the past six months, insider transactions show net selling. They sold 675.25 thousand shares across 51 transactions.

Short-term trend indicators are bearishly aligned (SMA20 -2.58%, SMA50 2.44%, SMA200 72.91%). The stock’s 14-day RSI is 48.24 (neutral), while the ATR of 2.52 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -8.58% below its high and over 467.06% above its low. Average 10-day trading volume of 202.74 thousand shares is below the 3-month average of 299.74 thousand, indicating normal recent market interest.

Our AI price prediction model suggests that Sionna Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.4%, with price expected at $42.95 by January 13, 2026, within a range of $41.30 to $44.90 3-Month Outlook: Projected rise of 163.47%, reaching $108.39 by March 30, 2026, with a range of $107.86 to $108.88. 1-Year Outlook: Projected gain of 81.6%, with price at $74.71 by December 30, 2026, within a range of $73.01 to $76.50.

currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Sionna Therapeutics, Inc. trading at a premium to the broader market with a P/E of -31.07. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $39.62, suggesting -3.69% downside. Our AI forecast model points to short-term strength (4.4% over two weeks), a medium-term rise (163.47% over three months), and a longer-term gain (81.6% over one year), with expected trading ranges indicating moderate volatility.

Sionna Therapeutics, Inc. trades at a P/E ratio of -31.07, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 5.44 trading at moderately above to book value. The P/FCF stands at -32.79, also below market averages.